A urinary tract infection (UTI) is an infection in any part of the urinary system. The urinary system includes kidneys, ureters, bladder and urethra. Antibiotics usually are the first treatment for urinary tract infections. Taking antibiotics, prescribed by a healthcare professional, at home can treat most UTIs. However, some cases may require treatment in the hospital. Often, urinary tract infection symptoms clear up within a few days of starting treatment. Women are at greater risk of developing a urinary tract infection compared to men.
The Global Urinary Tract Infection Therapeutic Market is estimated to account for US$ 8,923.7 Mn in terms of value by the end of 2022.
Increase in demand for urinary tract infection therapeutics due to the increase in prevalence of urinary tract infection around the globe is expected to propel growth of the global urinary tract infection therapeutic market during the forecast period. As a result, players in the market are focusing on developing or launching novel therapeutics in the market. In July 2019, the U.S Food and Drug Administration (FDA) approved Merck and Company's Recarbrio (imipenem, cilastatin, and relebactam), an antibacterial drug for the treatment of adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).
Increase in focus on the development of novel therapeutics to treat UTIs is expected to provide significant growth opportunities for players in the urinary tract infection therapeutic market. In February 2020, Allecra Therapeutics, a France-based pharmaceutical company, announced that its Exblifep (cefepime-enmetazobactam), a combination of a novel extended-spectrum beta-lactamase inhibitor, enmetazobactam, and fourth-generation cephalosporin cefepime, achieved primary endpoints in a clinical trial for complicated urinary tract infections.
Lack of awareness among people and side effects of UTI medication are major factors expected to hamper the growth of the urinary tract infection therapeutic market. For instance, like most antibiotics, the antibiotics that are commonly used to treat UTIs can lead to side effects in some people. Antibiotics can have side effects, such as fever, headache, diarrhea, vomiting, nausea, nerve damage, rash, and tendon ruptures. UTIs are the second most common type of infection in the body. Thus, it is important to be aware of urinary tract infection and its therapeutics.
Global Urinary Tract Infection Therapeutic Market - Impact of Coronavirus (Covid-19) Pandemic:
The COVID-19 outbreak had reduced access to other primary care services and resulted in a significant drop in non-COVID-19-related diagnoses, such as urinary tract infections. In short, the pandemic has resulted in fewer patients seeking primary care services and fewer diagnoses to avoid the risk of contracting COVID-19 infection. However, the increase in the rate of UTI diagnosis (in 2021) across the globe has positively impacted growth of the market, driving the growth of the global urinary tract infection therapeutic market.
To know the latest trends and insights prevalent in this market, click the link below:
The global urinary tract infection therapeutic market was valued at US$ 8,665.5 Mn in 2021 and is forecast to reach a value of US$ 10,686.5 Mn by 2028 at a CAGR of 3.0% between 2022 and 2028.
Among drug Quinolones segment held dominant position in the global urinary tract infection therapeutic market in 2021, accounting for 41.6% share in terms of value, increasing approval and launch of new products is expected to propel growth of the segment during the forecast period.
Increase in awareness about the association of diabetes and obesity with bladder dysfunction, rapid deployment of innovative technologies for UTI treatment, and increase in focus on the development of novel therapeutics are among the key trends driving the growth of the urinary tract infection therapeutic market. With the increase in prevalence of urinary tract infections, the demand for urinary tract infection therapeutics (novel therapeutics) is also increasing with a rapid pace, driving the growth of the market.
Major players operating in the global urinary tract infection therapeutic market include Pfizer, Novartis AG, Cipla Inc., Bayer AG, AstraZeneca, Shionogi & Co. Ltd., and GlaxoSmithKline PLC, among others.
In March 2021, Cipla Therapeutics, a commercial-stage pharmaceutical company, announced entering a strategic partnership to deliver sustained innovation and access to novel antibacterial drugs, particularly against bio-threats.
In October 2019, Cipla Limited announces the acquisition of a novel and patented anti-infective product, Elores, from Venus Remedies Limited for the Indian market to further strengthen its presence in the branded Indian critical care space and as a part of its agenda to contribute to the fight against Anti-Microbial Resistance (AMR).
In July 2019, Healthy.io announced an agreement with Walgreens Boots Alliance, Inc. placing Healthy.io's Dip UTI test kits in Boots pharmacies throughout the United Kingdom.